Zydus & CMS enter pact for Desidustat in Greater China

The agreement is for Desidustat, a novel oral HIF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease (CKD) not-on-dialysis and for the treatment of anemia CKD patients on dialysis in Greater China, Zydus said in a statement. "Under the license agreement, CMS will pay Zydus an initial upfront payment," it added.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news